Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 13, 2024

SELL
$83.81 - $99.0 $2.43 Million - $2.87 Million
-29,000 Reduced 79.45%
7,500 $655,000
Q4 2023

Feb 13, 2024

BUY
$76.22 - $98.51 $1.08 Million - $1.4 Million
14,200 Added 63.68%
36,500 $3.52 Million
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $1.05 Million - $1.16 Million
12,300 Added 123.0%
22,300 $1.97 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $447,474 - $598,077
-5,100 Reduced 33.77%
10,000 $972,000
Q4 2022

Sep 21, 2023

BUY
$80.93 - $108.63 $412,743 - $554,013
5,100 Added 51.0%
15,100 $1.56 Million
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $1.22 Million - $1.64 Million
15,100 New
15,100 $1.56 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Jefferies Financial Group Inc. Portfolio

Follow Jefferies Financial Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.